Sanara MedTech Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.12 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $34.88Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $320.5M Enterprise Value $351.5M Shares Outstanding 8.8M diluted Moat Rating Wide Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Sanara MedTech has successfully transitioned into a pure-play surgical business following the discontinuation of its chronic wound care (THP) operations in late 2025. This strategic shift delivers a cleaner financial profile characterized by industry-leading gross margins of ~93% and strong operating leverage. Growth is primarily driven by market share gains in its core soft tissue repair products (CellerateRX Surgical and BIASURGE) and expanded hospital and distributor networks. With a robust pipeline, including the anticipated Q1 2027 launch of OsStic, Sanara is well-positioned to capture significant market share in the surgical operating setting. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$32.00 Mean target$34.33 High · most bullish analyst$36.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $25.0015% Slower-than-anticipated hospital adoption, intense competition from larger wound care players, or delays in the FDA clearance of OsStic limit revenue growth. Tight interest coverage (1.5x) and high debt service costs pressure liquidity, forcing a dilutive capital raise or asset sales. Base CaseCentral scenario $34.3360% Matches the consensus meanSanara delivers on its reaffirmed FY 2026 revenue guidance of $116 million to $121 million (13% to 17% YoY growth) while maintaining gross margins of ~93%. The company continues to expand its distributor network and successfully prepares for the commercial launch of OsStic in Q1 2027. Debt is successfully serviced or refinanced under favorable terms. Bull CaseUpside scenario $37.8025% Accelerated market penetration of CellerateRX and BIASURGE, combined with an earlier-than-expected FDA clearance and highly successful launch of OsStic, drives revenue well above the high end of guidance. Operating leverage scales rapidly, leading to significant GAAP profitability and a major valuation re-rating toward peer multiples. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |